Provided are pharmaceutical compositions comprising glycopyrrolate, a beta2-adrenergic agonist, and optionally a corticosteroid. Preferred beta2-adrenergic agonists include indacaterol, formoterol, vilanterol, carmoterol and olodaterol. Preferred corticosteroids include fluticasone and mometasone. Particularly preferred compositions consist of glycopyrrolate, formoterol fumarate dihydrate and fluticasone furoate; glycopyrrolate, vilanterol trifenatate and fluticasone furoate; or glycopyrrolate and olodaterol hydrochloride monohydrate. The compositions can be used in the treatment of respiratory, inflammatory or obstructive airway diseases.